Cargando…
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
BACKGROUND: Metabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance. Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events. Telmisartan, an antihypertensiv...
Autores principales: | Vitale, Cristiana, Mercuro, Giuseppe, Castiglioni, Carlotta, Cornoldi, Alessandra, Tulli, Arianna, Fini, Massimo, Volterrani, Maurizio, Rosano, Giuseppe MC |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1174877/ https://www.ncbi.nlm.nih.gov/pubmed/15892894 http://dx.doi.org/10.1186/1475-2840-4-6 |
Ejemplares similares
-
Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study
por: Rosano, Giuseppe MC, et al.
Publicado: (2003) -
Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
por: Hirata, Takumi, et al.
Publicado: (2013) -
Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”
por: Hirata, Takumi, et al.
Publicado: (2014) -
Effects of telmisartan and losartan treatments on bone turnover
markers in patients with newly diagnosed stage I hypertension
por: Aydoğan, Berna İ, et al.
Publicado: (2019) -
Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open-label Study
por: Kalikar, Mrunalini, et al.
Publicado: (2017)